Free tool
FAERS Monitor: Pedmark
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212937 or its brand name (Pedmark, Sodium Thiosulfate). Reports on generic versions are filed under their own applications.
Reports
560
Serious
467
83% of reports
Hospitalization
196
Death reported
81
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use154
- calciphylaxis89
- nausea88
- drug ineffective57
- vomiting54
- metabolic acidosis31
- sepsis23
- condition aggravated21
- pruritus21
- fatigue20
- death19
- headache19
- erythema18
- pain17
- diarrhoea14
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 7 |
| 2011 | 19 |
| 2012 | 3 |
| 2013 | 11 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 15 |
| 2017 | 32 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 38 |
| 2021 | 45 |
| 2022 | 43 |
| 2023 | 41 |
| 2024 | 79 |
| 2025 | 68 |
| 2026 | 63 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,599 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| calciphylaxisSignal | 89 | 1915.3 | 1574.0 | 160,226 |
| metabolic acidosisSignal | 31 | 36.4 | 25.9 | 1,034 |
| sepsisSignal | 23 | 7.7 | 5.2 | 129 |
| off label useSignal | 154 | 6.6 | 5.8 | 759 |
| vomitingSignal | 54 | 4.3 | 3.3 | 137 |
| nauseaSignal | 88 | 4.2 | 3.4 | 218 |
| erythemaSignal | 18 | 3.3 | 2.1 | 27 |
| condition aggravatedSignal | 21 | 2.6 | 1.7 | 19 |
| pruritusSignal | 21 | 2.1 | 1.3 | 10 |
| drug ineffective | 57 | 1.6 | 1.3 | 14 |
| headache | 19 | 1.1 | 0.7 | 0 |
| pain | 17 | 1.0 | 0.7 | 0 |
| fatigue | 20 | 1.0 | 0.6 | 0 |
| death | 19 | 0.8 | 0.5 | 1 |
| diarrhoea | 14 | 0.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.